4D Molecular Therapeutics, Inc.

Contributing Author

Recent Articles by 4D Molecular Therapeutics, Inc.

Feb-13	4DMT Announces New Employment Inducement Grants FDMT GlobeNewswire
Feb-09	4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD FDMT GlobeNewswire
Jan-17	4DMT Announces New Employment Inducement Grants FDMT GlobeNewswire
Jan-07	4DMT Provides Company Update and Anticipated Development Milestones for 2026 FDMT +8.07% GlobeNewswire
Dec-17	4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease FDMT -20.05% GlobeNewswire
Dec-12	4DMT Announces New Employment Inducement Grants FDMT GlobeNewswire
Dec-08	4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference FDMT GlobeNewswire
Nov-20	4DMT to Participate in 8th Annual Evercore Healthcare Conference FDMT GlobeNewswire
Nov-17	4DMT Appoints Kristian Humer as Chief Financial Officer FDMT GlobeNewswire
Nov-14	4DMT Announces New Employment Inducement Grants FDMT GlobeNewswire
Nov-10	4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones FDMT GlobeNewswire
Nov-06	4DMT to Participate in Jefferies 2025 London Healthcare Conference FDMT GlobeNewswire
Nov-06	4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants FDMT GlobeNewswire
Nov-06	4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years FDMT GlobeNewswire
Oct-30	4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific FDMT GlobeNewswire
Oct-17	4DMT Announces New Employment Inducement Grants FDMT +14.53% FDMT GlobeNewswire
Oct-14	4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference FDMT GlobeNewswire
Oct-13	4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation FDMT +8.65% GlobeNewswire
Sep-12	4DMT Announces New Employment Inducement Grants FDMT GlobeNewswire
Sep-02	4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness FDMT GlobeNewswire
Aug-25	4DMT to Participate in Upcoming Investor Conferences FDMT GlobeNewswire
Aug-15	4DMT Announces New Employment Inducement Grants FDMT GlobeNewswire
Aug-11	4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones FDMT GlobeNewswire
Aug-06	4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference FDMT -5.29% GlobeNewswire
Jul-31	4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update FDMT +42.67% FDMT GlobeNewswire
Jul-24	4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists FDMT GlobeNewswire
Jul-11	4DMT Announces New Employment Inducement Grants FDMT GlobeNewswire
Jul-02	4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution FDMT GlobeNewswire
May-28	4DMT to Participate in Upcoming Investor Conferences FDMT GlobeNewswire
May-16	4DMT Announces New Employment Inducement Grants FDMT +10.47% FDMT +7.50% GlobeNewswire
May-08	4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones FDMT GlobeNewswire
May-05	4DMT to Participate in Upcoming Investor Conferences FDMT -5.05% GlobeNewswire
May-01	4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME FDMT GlobeNewswire

4D Molecular Therapeutics, Inc.

Recent Articles by 4D Molecular Therapeutics, Inc.

Upgrade your FINVIZ experience